Public Sector Pension Investment Board Has $5.14 Million Position in Omnicell, Inc. $OMCL

Key Points

• The Public Sector Pension Investment Board increased its stake in Omnicell, Inc. by 27.6% during the first quarter, owning 0.31% of the company worth over $5 million.
• Wall Street analysts have mixed opinions on Omnicell, with price targets ranging from $34.00 to $55.00 and a consensus rating of "Moderate Buy."
• Omnicell's latest quarterly earnings reported an increase in revenue to $290.56 million, beating estimates and showcasing a 5.0% year-over-year growth.

Public Sector Pension Investment Board boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 27.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 146,916 shares of the company's stock after acquiring an additional 31,765 shares during the period. Public Sector Pension Investment Board owned about 0.31% of Omnicell worth $5,136,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. raised its position in shares of Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after buying an additional 154,038 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after buying an additional 394,820 shares during the last quarter. Lazard Asset Management LLC increased its position in Omnicell by 81.6% during the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after purchasing an additional 737,536 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its position in Omnicell by 4.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock worth $53,290,000 after purchasing an additional 56,117 shares during the last quarter. Finally, Toronto Dominion Bank purchased a new position in shares of Omnicell in the fourth quarter valued at $30,637,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Wells Fargo & Company increased their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Piper Sandler decreased their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Benchmark decreased their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Bank of America raised their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Stock Up 0.8%

OMCL traded up $0.2670 during midday trading on Thursday, hitting $32.0170. 357,580 shares of the company's stock traded hands, compared to its average volume of 567,932. The company has a market cap of $1.47 billion, a PE ratio of 64.08, a price-to-earnings-growth ratio of 9.31 and a beta of 0.78. The stock's fifty day simple moving average is $29.49 and its 200-day simple moving average is $32.07. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. During the same quarter last year, the company posted $0.51 earnings per share. The company's revenue for the quarter was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.